110 related articles for article (PubMed ID: 28991002)
1. Estimating the Effect of Preventable Treatment Discontinuation on Health Outcomes.
Brookhart MA; Reams D; Dluzniewski PJ; Kshirsagar A; Walsh L; Bradbury BD
Epidemiology; 2018 Jan; 29(1):134-141. PubMed ID: 28991002
[TBL] [Abstract][Full Text] [Related]
2. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
3. Impact of calcimimetics in surgery of secondary hyperparathyroidism.
Ruiz J; Ríos A; Rodríguez JM; Llorente S; Hernández AM; Parrilla P
Endocrinol Diabetes Nutr; 2017 Jan; 64(1):59-61. PubMed ID: 28440773
[No Abstract] [Full Text] [Related]
4. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
Belozeroff V; Chertow GM; Graham CN; Dehmel B; Parfrey PS; Briggs AH
Value Health; 2015 Dec; 18(8):1079-87. PubMed ID: 26686794
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet and Clinical Outcomes in Dialysis.
Komaba H; Fukagawa M
Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
[TBL] [Abstract][Full Text] [Related]
7. Calcimimetics versus parathyroidectomy: What is preferable?
Rroji M; Spasovski G
Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
[TBL] [Abstract][Full Text] [Related]
8. [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
Zwiech R; Chrul S
Wiad Lek; 2012; 65(3):145-50. PubMed ID: 23289260
[TBL] [Abstract][Full Text] [Related]
9. [Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.].
Hamano N; Fukagawa M
Clin Calcium; 2017; 27(4):567-572. PubMed ID: 28336834
[TBL] [Abstract][Full Text] [Related]
10. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
[TBL] [Abstract][Full Text] [Related]
11. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
Reams BD; Dluzniewski PJ; Do TP; Yue SV; Bradbury BD; Kshirsagar AV; Brookhart MA
BMC Nephrol; 2015 Oct; 16():175. PubMed ID: 26510587
[TBL] [Abstract][Full Text] [Related]
13. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
[TBL] [Abstract][Full Text] [Related]
14. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
16. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
Yokoyama K; Kurita N; Fukuma S; Akizawa T; Fukagawa M; Onishi Y; Kurokawa K; Fukuhara S
Nephrol Dial Transplant; 2017 Mar; 32(3):534-541. PubMed ID: 26945054
[TBL] [Abstract][Full Text] [Related]
17. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
[TBL] [Abstract][Full Text] [Related]
18. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
19. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
Grzegorzewska AE; Niepolski L
Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
